UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors
  • Nov

    16

    Investing in Brighter Futures: UCB and the UCB Family Epilepsy Scholarship Program™

    Nov

    11

    UCB Announces 11 Inaugural Recipients of Annual Hidradenitis Suppurativa Scholarship™

    Nov

    06

    BE BOLD: BIMZELX® (bimekizumab-bkzx) builds on superior joint responses versus SKYRIZI® (risankizumab-rzaa) at Week 16, with clinical improvements sustained through Week 24

    Nov

    04

    UCB opens applications for 2027 UCB Myasthenia Gravis Scholarship™

    Oct

    23

    UCB Establishes the Emmanuel Janssen Endowed Chair for the Evaluation of Medicines at Brigham and Women's Hospital

    Oct

    16

    UCB announces U.S. FDA approval for ZILBRYSQ® (zilucoplan) autoinjector self-administration for adults living with generalized myasthenia gravis

    Oct

    12

    UCB Launches Wear It Out, a Community-Driven Program Created For and With People Living With Hidradenitis Suppurativa, Plaque Psoriasis, and Psoriatic Arthritis

    Oct

    09

    UCB Dedicates Site for New U.S. Biologics Manufacturing Campus in Georgia

    Sep

    30

    Inside a PowerHouSe: Conversations, Connection & Learning at the 2026 UCB HS Summit

    Sep

    29

    UCB data presented at 2026 AANEM Annual Meeting and MGFA Scientific Session underscore leadership in advancing targeted treatments for gMG